These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16835206)

  • 1. Postapproval drug safety.
    Abraham IL; MacDonald KM
    Health Aff (Millwood); 2006; 25(4):1186-7; author reply 1187-8. PubMed ID: 16835206
    [No Abstract]   [Full Text] [Related]  

  • 2. Spending on postapproval drug safety.
    Ridley DB; Kramer JM; Tilson HH; Grabowski HG; Schulman KA
    Health Aff (Millwood); 2006; 25(2):429-36. PubMed ID: 16522583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Postapproval Evidence Generation on the Biopharmaceutical Industry.
    Milne CP; Cohen JP; Felix A; Chakravarthy R
    Clin Ther; 2015 Aug; 37(8):1852-8. PubMed ID: 26143223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDUFA reauthorization--drug safety's golden moment of opportunity?
    Hennessy S; Strom BL
    N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
    [No Abstract]   [Full Text] [Related]  

  • 5. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

  • 6. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 7. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J
    Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
    [No Abstract]   [Full Text] [Related]  

  • 8. What's so great about newness?
    Light DW
    Health Aff (Millwood); 2007; 26(6):1793; author reply 1793-4. PubMed ID: 17978409
    [No Abstract]   [Full Text] [Related]  

  • 9. [Conference 1. An economic observatory for orphan drugs: myth or reality?].
    Duguet C; Ferry A
    Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173
    [No Abstract]   [Full Text] [Related]  

  • 10. Post-marketing strategies for medicines.
    Breckenridge A
    Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
    [No Abstract]   [Full Text] [Related]  

  • 11. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of Authorized Generics in Postapproval Surveillance of Generic Drug Products.
    Gagne JJ; Sarpatwari A; Desai RJ
    Clin Pharmacol Ther; 2019 Feb; 105(2):313-315. PubMed ID: 30593655
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 14. Bolstering the FDA's drug-safety authority.
    Schultz WB
    N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract]   [Full Text] [Related]  

  • 15. The drugs industry: a bad product well marketed.
    Abbasi K
    J R Soc Med; 2012 Jul; 105(7):275. PubMed ID: 22843642
    [No Abstract]   [Full Text] [Related]  

  • 16. User-fee bill passes US Senate, but legislative hurdles remain.
    Fox JL
    Nat Biotechnol; 2007 Jun; 25(6):611. PubMed ID: 17557086
    [No Abstract]   [Full Text] [Related]  

  • 17. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 19. Post-marketing observational trials and catastrophic health expenditure.
    Yudkin JS
    BMJ; 2012 Jun; 344():e3987. PubMed ID: 22692653
    [No Abstract]   [Full Text] [Related]  

  • 20. Post-marketing studies of new insulins: sales or science?
    Gale EA
    BMJ; 2012 Jun; 344():e3974. PubMed ID: 22692652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.